Canaccord lowered the firm’s price target on AxoGen (AXGN) to $24 from $26 and keeps a Buy rating on the shares. The firm updated its model to reflect Q125 results and the subsequent 10Q release. As a reminder, the company reiterated FY25 revenue and gross margin guidance on its Q125 call.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXGN:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue